Professor Rothwell is a clinical neurologist with an interest in stroke. He was appointed as Clinical Lecturer in Oxford in 1996, was awarded an MRC Senior Clinical Fellowship in 2000, and was given the title of Professor of Clinical Neurology at the University of Oxford in 2004. He founded the Stroke Prevention Research Unit in 2000, which has since published over 250 scientific papers.
In addition to prevention of stroke, his research interests include hypertension, the risks and benefits of aspirin, and the more general theme of how best to apply the results of clinical trials and other forms of research to clinical decisions with individual patients in routine clinical practice.
Professor Rothwell’s responsibilities outside Oxford include editorial duties for several international scientific journals, membership of committees of several multicentre trials, and several national and international scientific and advisory committees.
Awards Training and Qualifications
- 1987 MB ChB, University of Edinburgh
- 1995 MD, University of Edinburgh
- 1999 PhD, University of Edinburgh
- 2002 FRCP, London
- 2008 FMedSci, Academy of Medical Sciences
- 2009 Senior Investigator Award, National Institute of Health Research
- 2009 Award for Outstanding Contribution to Clinical Research, British Medical Journal
- 2009 Foulkes Foundation Medal, Academy of Medical Sciences
- 2010 Bienniel Award for Oustanding Contribution to Stroke Research, World Stroke Organisation
- 2011 Honorary Professorial Fellowship, George Institute, University of Sydney
- 2011 RD Wright Lectureship, High Blood Pressure Reseach Council of Australia
- 2011 Senior Investigator Award, Wellcome Trust
MD PhD FRCP
Head of the Centre for the Prevention of Stroke and Dementia and Professor of Clinical Neurology
Main research interests are in the causes of stroke and improving the prevention of stroke, particularly after a TIA or minor stroke. Other interests include the more general theme of how best to apply the results of clinical trials and other forms of research to clinical decisions with individual patients in routine clinical practice, hypertension, and the effects of aspirin on non-vascular outcomes, such as cancer.
Sources of Funding
Antiplatelet Treatment After Transient Ischemic Attack and Ischemic Stroke in Patients With Cerebral Microbleeds in 2 Large Cohorts and an Updated Systematic Review.
Lau KK. et al, (2018), Stroke
Hospital and Institutionalisation Care Costs after Limb and Visceral Ischaemia Benchmarked Against Stroke: Long-Term Results of a Population Based Cohort Study.
Luengo-Fernandez R. et al, (2018), Eur J Vasc Endovasc Surg
Age-Specific Associations of Renal Impairment With Magnetic Resonance Imaging Markers of Cerebral Small Vessel Disease in Transient Ischemic Attack and Stroke.
Liu B. et al, (2018), Stroke, 49, 899 - 904
Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke.
Hilkens NA. et al, (2018), Neurology, 90, e683 - e689
External Validation of Risk Scores for Major Bleeding in a Population-Based Cohort of Transient Ischemic Attack and Ischemic Stroke Patients.
Hilkens NA. et al, (2018), Stroke, 49, 601 - 606